Evidence map›Paper›PMID 36898086›Full record

ArticleThe journal of physical chemistry letters2023

Critical Non-Covalent Binding Intermediate for an Allosteric Covalent Inhibitor of SUMO E1.

Shristi Pawnikar, Apurba Bhattarai, S Xiaohu Ouyang, Ramir Vega, Yuan Chen, Yinglong Miao

Abstract read
In one paragraph

Article in The journal of physical chemistry letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shristi PawnikarCenter for Computational Biology and Department of Molecular Biosciences, University of Kansas, Lawrence, Kansas 66047, United States.
Apurba BhattaraiCenter for Computational Biology and Department of Molecular Biosciences, University of Kansas, Lawrence, Kansas 66047, United States.
S Xiaohu OuyangSUMO Biosciences, Inc., 2265 East Foothill Boulevard, Pasadena, California 91107, United States.
Ramir VegaDepartment of Molecular Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, California 91010, United States.
Yuan ChenDepartment of Surgery and Moores Cancer Center, UC San Diego Health, 3855 Health Sciences Drive, La Jolla, California 92037, United States.
Yinglong MiaoCenter for Computational Biology and Department of Molecular Biosciences, University of Kansas, Lawrence, Kansas 66047, United States.ORCID 0000-0003-3714-1395

Funding

Targeting c-Myc and Proteasome Inhibitor Resistance in Multiple MyelomaR01CA212119 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, YUAN · 2017 to 2021
$2.8M
SUMO Modification and Cancer TherapyR01CA265410 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, YUAN · 2021 to 2025
$2.5M
K-Ras sumoylation in cell proliferation and transformationR01CA216987 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CHEN, YUAN, DAI, WEI · 2017 to 2021
$2.5M
Design of a Covalent Inhibitor for c-Myc-Dependent CancersR44CA189499 · NCI · SUVALENT THERAPEUTICS, INC. · PI OUYANG, SHAWN XIAOHU · 2015 to 2016
$2.0M
NCI NIH HHS R01 CA212119NCI NIH HHS R01 CA216987NCI NIH HHS R01 CA265410NCI NIH HHS R44 CA189499
6 · The paper itself

Abstract

Post-translational modifications by small ubiquitin-like modifiers (SUMOs) are dysregulated in many types of cancers. The SUMO E1 enzyme has recently been suggested as a new immuno-oncology target. COH000 was recently identified as a highly specific allosteric covalent inhibitor of SUMO E1. However, a marked discrepancy was found between the X-ray structure of the covalent COH000-bound SUMO E1 complex and the available structure-activity relationship (SAR) data of inhibitor analogues due to unresolved noncovalent protein-ligand interactions. Here, we have investigated noncovalent interactions between COH000 and SUMO E1 during inhibitor dissociation through novel Ligand Gaussian accelerated molecular dynamics (LiGaMD) simulations. Our simulations have identified a critical low-energy non-covalent binding intermediate conformation of COH000 that agreed excellently with published and new SAR data of the COH000 analogues, which were otherwise inconsistent with the X-ray structure. Altogether, our biochemical experiments and LiGaMD simulations have uncovered a critical non-covalent binding intermediate during allosteric inhibition of the SUMO E1 complex.

Indexed as

UbiquitinUbiquitin-Conjugating EnzymesLigandsMolecular ConformationMolecular Dynamics SimulationLigandsUbiquitinUbiquitin-Conjugating Enzymes

Identifiers

PMID36898086
PMCPMC10373441

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.